Sniecinski Megan 4
4 · BIOCRYST PHARMACEUTICALS INC · Filed Jul 3, 2019
Insider Transaction Report
Form 4
Sniecinski Megan
Chief Business Officer
Transactions
- Award
Emp. Stock Option (Right to Buy)
2019-07-01+500,000→ 500,000 totalExercise: $3.71From: 2020-07-01Exp: 2029-07-01→ Common Stock (500,000 underlying)
Footnotes (1)
- [F1]Inducement option grant becomes exercisable at the rate of 30% on the first anniversary of the grant date with the remainder vesting in three equal installments on the second, third and fourth anniversaries of the grant date.